What is the best immunosuppression for the elderly kidney transplantation patient?;Quelle immunosuppression pour le patient âgé en transplantation rénale ?

Nephrologie et Therapeutique

Volumn 4, Issue SUPPL. 3, 2008, Pages

  Ladriere M ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Anticalcineurins; Elderly patient; Immunosuppression; Kidney transplantation; Proliferation signal inhibitors

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; DRUG WITHDRAWAL; GERIATRIC CARE; HISTOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MORTALITY; SURVIVAL;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; AGING; CALCINEURIN; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2;

EID: 55749114725     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1769-7255(08)74231-7     Document Type: Article

References (41)

1. Hourmant M. Transplantation rénale chez le sujet âgé. Rev Prat 55 (2005) 2263-2267
2. Rerolle J.P., Szelag J.C., Diaconita M., Saada F., Aldigier J.C., and Le Meur Y. Renal transplantation in the elderly: a survey. Nephrol Ther 2 (2006) 8-14
3. Rao P.S., Merion R.M., Ashby V.B., Port F.K., Wolfe R.A., and Kayler L.K. Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients. Transplantation 83 (2007) 1069-1074
4. Savoye E., Tamarelle D., Chalem Y., Rebibou J.M., and Tuppin P. Survival benefits of kidney transplantation with expanded criteria deceased donors in patients aged 60 years and over. Transplantation 84 (2007) 1618-1624
5. Doyle S.E., Matas A.J., Gillingham K., and Rosenberg M.E. Predicting clinical outcome in the elderly renal transplant recipient. Kidney Int 57 (2000) 2144-2150
6. Kauffman H.M., McBride M.A., Cors C.S., Roza A.M., and Wynn J.J. Early mortality rates in older kidney recipients with comorbid risk factors. Transplantation 83 (2007) 404-410
7. Oniscu G.C., Brown H., and Forsythe J.L. How old is old for transplantation?. Am J Transplant 4 (2004) 2067-2074
8. Meier-Kriesche H.U., Ojo A.O., Hanson J.A., and Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 59 (2001) 1539-1543
9. Martins P.N., Pratschke J., Pascher A., Fritsche L., Frei U., Neuhaus P., et al. Age and immune response in organ transplantation. Transplantation 79 (2005) 127-132
10. de Fijter J.W. The impact of age on rejection in kidney transplantation. Drugs Aging 22 (2005) 433-449
11. Arns W., Citterio F., and Campistol J.M. "Old-for-old"-new strategies for renal transplantation. Nephrol Dial Transplant 22 (2007) 336-341
12. Waiser J., Schreiber M., Budde K., Fritsche L., Böhler T., Hauser I., et al. Age-matching in renal transplantation. Nephrol Dial Transplant 15 (2000) 696-700
13. Danovitch G.M., Gill J., and Bunnapradist S. Immunosuppression of the elderly kidney transplant recipient. Transplantation 84 (2007) 285-291
14. Pallet N., Anglicheau D., Martinez F., Mamzer M.F., Legendre C., and Thervet E. Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donor. Transplantation 81 (2006) 949-952
15. Mourad G., Rostaing L., Legendre C., Garrigue V., Thervet E., and Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584-590
16. Segoloni G.P., Messina M., Squiccimarro G., Mazzucco G., Torta E., Leonardi G., et al. Preferential allocation of marginal kidney allografts to elderly recipients combined with modified immunosuppression gives good results. Transplantation 80 (2005) 953-958
17. th Congress of the European Transplant Coordinators Organization 29 September - 3 October 2007, Prague, Czech Republic. Transpl int 2007;20(Suppl 2):X.
18. Mourad G., Rostaing L., Legendre Ch., and Myriade FR01 study group. Assessment ot two strategies of neoral administration, early versus delayed, on renal function and efficacyin de novo renal transplant receiving myfortic, steroids, and anti IL-2R antibodies: 12 month results of a randomized multicentre, open, prospective controlled study. Transplant proc 37 (2005) 920-922
19. th Annual Joint Meeting of the American Society of Transplant surgeons and the American Society of Transplantation, 21 - 25 may 2005, Seattle, Washington USA. Am J Transplant 5 (2005) 539
20. Vitko S., Tedesco H., Eris J., Pascual J., Whelchel J., Magee J.C., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6 month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626-635
21. Salvadori M, Scolari MP, Stefoni S, et al. Randomized trial of sodium mycophenolate and basiliximab in combination with reduced or standard cyclosporine in old recipients of kidney transplant. [Abstract] 13th Congress of the European Society for Organ Transplantation and the 15th Congress of the European Transplant Coordinators Organization 29 September - 3 October 2007, Prague, Czech Republic. Transplant Int 2007; 20(Suppl 2):X.
22. Arbogast H., Hückelheim H., Schneeberger H., Illner W.D., Tarabichi A., Fertmann J., et al. A calcineurin antagonistfree induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial. Clin Transplant 19 (2005) 309-315
23. Rostaing L., Cantarovich D., Mourad G., Budde K., Rigotti P., Mariat C., et al., CARMEN study group. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumabinduction in renal transplantation. Transplantation 79 (2005) 807-814
24. Vincenti F., Schena F.P., Paraskevas S., Hauser I.A., Walker R.G., Grinyo J., and FREEDOM study group. A Randomized, multicenter study of steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 8 (2008) 307-316
25. Heifets M., Saeed M.I., Parikh M.H., Sierka D., and Kumar M.S. Induction immunosuppression in kidney transplant recipients older than 60 years of age: safety and efficacy of ATGAM OKT3 and Simulect. Drugs Aging 21 (2004) 747-756
26. Vincenti F., de Andrés A., Becker T., Choukroun G., Cole E., González-Posada J.M., et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transplant Int 19 (2006) 446-457
27. Kasiske B.L., Chakkera H.A., Louis T.A., and Ma J.Z. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11 (2000) 1910-1917
28. Frimat L., Cassuto-Viguier E., Charpentier B., Noël C., Provôt F., Rostaing L., et al. Impact of cyclosporine reduction with MMF : a randomized trial in chronic allograft dysfunction The "reference" study. Am J Transplant 6 (2006) 2725-2734
29. Ekberg H., Grinyó J., Nashan B., Vanrenterghem Y., Vincenti F., Voulgari A., et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 7 (2007) 560-570
30. Cibrik D., Meier-Kriesche H.U., Bresnahan B., Wu Y.M., Klintmalm G., Kew C.E., et al. Myfortic-US01 Renal Transplant Study Group. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. Clin Transplant 21 (2007) 192-201
31. Morelon E., Patey N., Rerolle J.P., et al. Peut-on se passer des inhibiteurs de la calcineurine en transplantation rénale ?. Actualités néphrologiques de Necker (2003) 299-310
32. Johnson D.W., Nicol D.L., Purdie D.M., Preston J.M., Brown A.M., Hawley C.M., et al. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?. Transplantation 73 (2002) 1158-1163
33. Meier-Kriesche H.U., Morris J.A., Chu A.H., Steffen B.J., Gotz V.P., Gordon R.D., et al. Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients. Nephrol Dial Transplant 19 (2004) 2864-2869
34. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., and Kahan B.D. Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883-889
35. Webster A.C., Lee V.W., Chapman J.R., and Craig J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression transplant recipients: a systematic review and metaanalysis of randomized trial. Transplantation 81 (2006) 1234-1248
36. Furian L., Baldan N., Margani G., Ekser B., Silvestre C., Marchini F., et al. Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors. Clin Transplant 21 (2007) 57-62
37. Cruzado J.M., Bestard O., Riera L., Torras J., Gil-Vernet S., Serón D., et al. Immunosuppression for dual kidney transplantation with marginal organs: the old is better yet. Am J Transplant 7 (2007) 639-644
38. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 (2005) 770-781
39. Gallon L.G., Winoto J., Leventhal J.R., Parker M.A., and Kaufman D.B. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 1 (2006) 1029-1038
40. Curtis J. Corticosteroids and kidney transplantation. C J Am Soc Nephrol 1 (2006) 907-908
41. Augustine J.J., and Hricik D.E. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 1 (2006) 1080-1089